While Eli Lilly and Novo Nordisk rake in tens of billions from obesity drugs like Ozempic, Wegovy, and Zepbound, Johnson & Johnson is publicly walking away and re anchoring its growth story around oncology.
Every major pharmaceutical company is racing into obesity drugs like Ozempic, Wegovy, and Zepbound. Johnson & Johnson is publicly walking away.
That contrast is the throughline in the June 18 STAT+ Pharmalittle roundup by columnist Ed Silverman, which flags J&J's "focus on cancer" framing as one of the day's notable pharma storylines. The other items in the roundup — an FDA advisory panel vote on Moderna's flu vaccine and Biogen's deal to acquire RayThera for up to $1 billion — are discrete news items. The J&J thread is a strategic signal: in a quarter when the rest of the industry is pouring resources into the most valuable new drug category in a generation, the largest healthcare conglomerate is leaning the other way.
GLP-1 drugs, a class that includes Eli Lilly's Zepbound and Novo Nordisk's Ozempic and Wegovy, work by mimicking a gut hormone that suppresses appetite and regulates blood sugar. The category has moved from a diabetes treatment into the most-watched corner of the pharmaceutical industry, with tens of billions of dollars in annual revenue and continued double-digit growth. Every major pharma executive is now asked about their GLP-1 strategy on earnings calls, and "are you in or out" has become the defining question of the current deal cycle.
J&J's answer, per the Pharmalittle column, is cancer. The company is re-anchoring its growth narrative around oncology rather than chasing the obesity market, framing itself as a cancer-focused company — a positioning the Pharmalittle column flagged as the day's most notable pharma signal. The acquisition of Halda Therapeutics, a prostate-cancer platform, serves as the proof point. Prostate cancer is a competitive indication, with several approved therapies and a long pipeline of new ones, and Halda's lead program is an oral therapy for prostate cancer. The deal gave J&J an oncology pipeline asset rather than a GLP-1 foothold, and it came after J&J's 2023 spin-off of Kenvue, its consumer health arm — leaving J&J organized around pharmaceuticals and medtech, a structure the company has pointed to in explaining its strategic choices.
The strategic question is whether focus is a discipline or a retreat. Oncology is a deep, durable market with high unmet need, and the category rewards companies that can build a multi-asset portfolio over a decade rather than chase a single breakout indication. The GLP-1 market is growing faster than any other therapeutic category, and opting out means accepting that Eli Lilly and Novo Nordisk, plus a queue of would-be challengers, will capture share that J&J could have contested. Whether J&J's current oncology revenue rivals Merck's Keytruda franchise or Bristol Myers Squibb's portfolio is a question the "framing itself as a cancer-focused company" positioning cannot answer on its own.
For now, J&J is framing the bet as a deliberate choice, not an absence. Whether investors and analysts accept that framing will depend on what the cancer pipeline delivers, starting with the Halda prostate-cancer program's clinical readouts, and on how the company handles the GLP-1 question the next time an analyst raises it on an earnings call.